Key Construction Projects in Guangdong Province 2023

Apr.19.2023
Key Construction Projects in Guangdong Province 2023
Guangdong Province 2023 construction plan includes four electronic cigarette-related projects, with a total investment of 585 million yuan.

Recently, the Guangdong Province 2023 Key Construction Project Plan was approved at the first session of the 14th Guangdong Provincial People's Congress. According to the notification issued by the Guangdong Provincial Development and Reform Commission, a total of 1,530 key projects will be arranged for 2023 in the province, with a total investment of CNY 8.5 trillion and an annual planned investment of CNY 1 trillion. Additionally, 1,090 provincial key preliminary construction projects will be arranged for preliminary work, with an estimated total investment of CNY 4.6 trillion.


Out of 1090 key construction projects, there are four electronic cigarette-related company factories included: Macrell, Smoore, Botton, and Han Qingda. These four projects are located in Jiangmen, Huizhou, and Foshan, with a total investment of 5.85 billion yuan.


The following project information is disclosed:


McAvell establishes electronic technology industrial park in Jiangmen.


The McGregor Electronic Technology Industrial Park Project is located in the Jianghai district of Jiangmen city, Guangdong province.


The total project investment amounts to 3 billion yuan. As of the end of 2022, a cumulative investment of 1 billion yuan has been completed, with plans to invest an additional 200 million yuan in 2023.


The project involves the construction of new factory buildings for the production of high-end electronic atomizer core components and other electronic device manufacturing.


The construction period will start in 2019 and end in 2024.


McWherter Project Information | Image source: Guangdong Provincial Development and Reform Commission


Simula establishes new materials technology industrial park in Jiangmen.


The Simore New Materials Technology Industrial Park project is located in Jiangmen City, Guangdong Province, China.


The total project investment is 1 billion yuan. As of the end of 2022, 36 million yuan has been invested cumulatively, and there are plans to invest 150 million yuan in 2023.


The project construction includes the establishment of a research, development, production, and sales headquarters for electronic heating elements and atomized materials.


The construction period is from 2022 to 2025.


Smor Project Information | Image Source: Guangdong Development and Reform Commission


China's "Boton" has built its Zhongkai "Boton" electronic atomizer headquarters and intelligent manufacturing base in Huizhou.


The headquarters and intelligent manufacturing base project of Zhongkai Podton Electronic Atomizer in China is located in Huizhou City, Guangdong Province.


The total investment of the project is 1.2 billion yuan, with plans to invest an additional 500 million yuan in 2023.


The construction project includes the production and operation of electronic atomizers, medical equipment and other related products.


The construction is scheduled to take place from 2023 to 2025.


Information about China's Bode project | Image source: Guangdong Development and Reform Commission.


Hanqingda establishes High Ming Intelligent Manufacturing Base in Foshan.


The HQD project for the construction of a high-tech manufacturing base is located in the Hecheng Street area of Foshan City, Guangdong Province.


The total investment in the project is 650 million yuan, with plans to invest an additional 100 million yuan by 2023.


The construction project includes facilities such as an e-cigarette production plant and planned supporting infrastructure like the first and last transit stops.


The construction period for the project is from 2023 to 2025.


Project Information of Hanqingda | Image Source: Guangdong Provincial Development and Reform Commission


For more related news, please follow 2FIRSTS.


Further Reading:


Semiconductor manufacturer SMIC reports a 97.7% decrease in revenue in the Chinese mainland market for the first quarter, while overseas markets experience a growth of 58.2%.


Macquarie plans to buy 3.5 billion yuan of structured deposits from Bank of China.


China's Boton is reportedly planning to purchase industrial land in Huizhou to construct a new headquarters and a manufacturing base for electronic atomizers.


References:


Notice from Guangdong Provincial Development and Reform Commission regarding the issuance of the 2023 major construction project plan for Guangdong Province.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

 PMI Opens Generative AI Center in Portugal to Support Global Operations
PMI Opens Generative AI Center in Portugal to Support Global Operations
According to information released by Portugal’s Trade & Investment Agency (AICEP) in July 2026, Philip Morris International (PMI) has established a global Generative Artificial Intelligence Factory (GenAI Factory) at its Portuguese subsidiary Tabaqueira. The center will support PMI’s global operations by developing and deploying AI solutions focused on industrial process optimization, data analytics, operational automation and AI application development. The initiative strengthens Portugal’s role in PMI’s global technology and innovation network.
Aug.27
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia’s withdrawal of its appeal in a landmark liquid-nicotine case has left a High Court ruling that struck down the 2023 nicotine exemption in force, bringing liquid and gel nicotine used in vaping products back under the Poisons Act 1952. At the same time, the Control of Smoking Products for Public Health Act 2024 continues to provide a regulatory framework for vaping products, creating uncertainty over retail sales, taxation and existing inventory. MPs are calling for nicotine vape sales and excise collection to stop, including refunds of more than RM354 million collected since 2023, while industry and consumer groups are asking the government to clarify the current legal position.
Sep.04
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22